Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

Abstract Background Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cance...

Full description

Saved in:
Bibliographic Details
Main Authors: Jinghan Zhu, Yixiao Xiong, Yuxin Zhang, Huifang Liang, Kun Cheng, Yuanxiang Lu, Guangzhen Cai, Yang Wu, Yunhui Fan, Xiaoping Chen, Hong Zhu, Zeyang Ding, Wanguang Zhang
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Communications
Subjects:
Chemo‐immunotherapy
Ferroptosis
Intrahepatic cholangiocarcinoma
Lactylation
Mevalonate pathway
PCK1
Online Access:https://doi.org/10.1002/cac2.70036
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cac2.70036

Similar Items